BioScrip, Inc. (BIOS) Downgraded by BidaskClub
BidaskClub downgraded shares of BioScrip, Inc. (NASDAQ:BIOS) from a strong-buy rating to a buy rating in a research report sent to investors on Tuesday morning.
A number of other analysts have also recently weighed in on the company. ValuEngine raised BioScrip from a sell rating to a hold rating in a research report on Thursday, July 13th. Zacks Investment Research raised BioScrip from a hold rating to a buy rating and set a $3.00 price target for the company in a research report on Wednesday, July 5th. Finally, Barrington Research boosted their price target on BioScrip to $3.50 and gave the stock an outperform rating in a research report on Monday, June 26th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. BioScrip presently has an average rating of Buy and an average price target of $3.50.
Shares of BioScrip (BIOS) remained flat at $2.67 during midday trading on Tuesday. 274,181 shares of the stock traded hands. BioScrip has a 1-year low of $0.98 and a 1-year high of $3.43. The firm’s market cap is $323.02 million. The company’s 50 day moving average price is $2.77 and its 200 day moving average price is $1.96.
BioScrip (NASDAQ:BIOS) last announced its quarterly earnings results on Thursday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $217.80 million during the quarter, compared to the consensus estimate of $230.23 million. During the same period in the prior year, the company earned ($0.17) earnings per share. BioScrip’s revenue was down 8.7% on a year-over-year basis. Analysts predict that BioScrip will post ($0.38) earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. Gilder Gagnon Howe & Co. LLC boosted its position in BioScrip by 248.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 15,211,136 shares of the company’s stock valued at $41,298,000 after buying an additional 10,845,410 shares in the last quarter. FMR LLC boosted its position in BioScrip by 36.1% in the first quarter. FMR LLC now owns 4,803,000 shares of the company’s stock valued at $8,165,000 after buying an additional 1,273,205 shares in the last quarter. Wynnefield Capital Inc. boosted its position in BioScrip by 2.7% in the first quarter. Wynnefield Capital Inc. now owns 3,800,000 shares of the company’s stock valued at $6,460,000 after buying an additional 100,000 shares in the last quarter. State Street Corp boosted its position in BioScrip by 10.6% in the fourth quarter. State Street Corp now owns 1,456,697 shares of the company’s stock valued at $1,515,000 after buying an additional 139,110 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in BioScrip by 15.3% in the first quarter. Geode Capital Management LLC now owns 944,054 shares of the company’s stock valued at $1,604,000 after buying an additional 125,098 shares in the last quarter. 83.22% of the stock is owned by institutional investors and hedge funds.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.